Phenylketonuria provides a human model for the study of the effect of phenylalanine on brain function. Although irreversible mental retardation is preventable through newborn diagnosis and dietary phenylalanine restriction, controversy exists regarding the effects of increased concentrations of phenylalanine in older patients. We have studied ten older, treated, phenylketonuric patients using a triple-blind, multiple trials, crossover design. Each patient was tested at the end of each of three 1-wk periods of high or low phenylalanine intakes. Tests included a repeatable battery of neuropsychological tests, analysis of plasma amino acids, and measurement of urine amino acids, phenyl organic acids, dopamine, and serotonin. In all 10 patients plasma phenylalanine rose (900-4,000 microM). In 9 of 10 patients there was an inverse relationship between plasma phenylalanine and urine dopamine excretion. When blood phenylalanine was elevated, these patients had prolonged performance times on neuropsychological tests of higher but not lower integrative function. Urinary serotonin fell during phenylalanine loading in six patients. The concentration of phenylacids in the urine was not proportional to the plasma phenylalanine at concentrations below 1.5 mM. In one patient, neither performance time nor dopamine excretion varied as blood phenylalanine rose or fell. We interpret these data as follows: blood phenylalanine above 1.3 mM impairs performance on neuropsychological tests of higher integrative function, this effect is reversible, and one mechanism may […] Abstract Phenylketonuria provides a human model for the study of the effect of phenylalanine on brain function. Although irreversible mental retardation is preventable through newborn diagnosis and dietary phenylalanine restriction, controversy exists regarding the effects of increased concentrations of phenylalanine in older patients. We have studied ten older, treated, phenylketonuric patients using a triple-blind, multiple trials, crossover design. Each patient was tested at the end of each of three 1-wk periods of high or low phenylalanine intakes. Tests included a repeatable battery of neuropsychological tests, analysis of plasma amino acids, and measurement of urine amino acids, phenyl organic acids, dopamine, and serotonin. In all 10 patients, plasma phenylalanine rose (9004,000 AM). In 9 of 10 patients there was an inverse relationship between plasma phenylalanine and urine dopamine excretion. When blood phenylalanine was elevated, these patients had prolonged performance times on neuropsychological tests of higher but not lower integrative function. Urinary serotonin fell during phenylalanine loading in six patients. The concentration of phenylacids in the urine was not proportional to the plasma phenylalanine at concentrations below 1.5 mM. In one patient, neither performance time nor dopamine excretion varied as blood phenylalanine rose or fell. We interpret these data as follows: blood phenylalanine above 13 mM impairs performance on neuropsychological tests of higher integrative function, this effect is reversible, and one mechanism may involve impaired biogenic amine synthesis.
Introduction plasma phenylalanine is normalized before age 3 wk through dietary restriction of phenylalanine, irreversible mental retardation is prevented (2) . The mechanisms for producing this permanent structural damage remain unclear, but several hypotheses have developed. Decreased or abnormal myelin formation and/or impaired oligodendroglial migration during the first 6 mo of postpartum brain development are the most probable mechanisms (3) (4) (5) (6) (7) .
Controversy persists regarding possible effects of elevated phenylalanine on brain function when development is nearly complete in older, treated patients with PKU. Whether or not elevated concentrations of phenylalanine disturb central nervous system function in these patients is unknown. Since -1 in 16 ,000 Caucasian newborns (Georgia statistics) (8) is affected with PKU, and effective newborn screening has prevented permanent brain damage since 1970 in the newborn screenee, an answer to the question of whether high plasma phenylalanine affects mental function becomes more urgent for this accumulating population.
Silverman and Guthrie (unpublished observations) approached the question by administering one loading dose of phenylalanine to control subjects, heterozygotes, and homozygous affected patients with PKU and compared errors in response time among the three groups. Their results suggested a difference among the three groups which related directly to the concentrations of plasma phenylalanine achieved.
In 1980, Waisbren et al. (9) on 81 children, 38 of whom had continued the diet beyond 6 yr of age and 43 of whom had discontinued at 6 yr of age, were reported in 1982. Results at 8 yr of age showed slightly lower achievement in reading and spelling in the discontinuers. No significant difference in IQ between the groups was observed after this 2-yr interval (11) . Brunner et al. (12) in a recent study (1983) reported a negative correlation between performance on neuropsychological tests and serum phenylalanine concentration on the day of testing in a group of early treated patients age 6-13 yr. Neither of these studies used the patient as his/her own control. Interindividual variation, differences in phenylalanine concentrations achieved and in techniques used by collaborating centers have hindered interpretation of results.
In in vitro systems, phenylalanine influences the synthesis critical compounds in neurotransmission (13). Both tyrosine-3-hydroxylase (E.C.C. 1.14.16.2) and tryptophan-5-hydroxylase (E.C.C. 1.14.16.4) are rate-limiting enzymes in the synthesis of dopamine and serotonin, respectively, and are competitively inhibited by phenylalanine at millimolar concentrations (14, 15) . Another potential inhibitory effect of phenylalanine on biogenic amine synthesis is through impaired uptake of tyrosine and tryptophan across the blood-brain barrier. Phenylalanine, tyrosine, and tryptophan share the same transport system and compete for a common transport function at physiologic concentrations (16) . Since transport of amino acids across the blood-brain barrier is the rate limiting step in the movement of amino acids from plasma to brain, and since their plasma concentration is near saturation of their transporter proteins, increased concentrations of plasma phenylalanine could limit the transport of tyrosine and tryptophan and thus their availability to the brain cell membrane for neuropeptide synthesis or conversion to biogenic amines (16) (17) (18) (19) .
The current study compares specific neuropsychological tests with changes in plasma phenylalanine and biogenic amine production in young adults and older children with PKU. Although the dopamine excreted in the urine is a reflection of multiple sources of dopamine synthesis (20) , we chose to measure urine dopamine, since it reflects 24-h production of the amine, not an acute level, and because urine collection is a noninvasive method of obtaining biologic fluids. Assessment is made of competitive inhibition by phenylalanine of tyrosine and tryptophan transport by kidney tubule. We use a tripleblinded, crossover, clinical protocol to circumvent the influence of individual variation in this disorder (21, 22) .
Methods
Study design. 10 patients with PKU, aged 6-24 yr, were admitted on a 21-d protocol to the Emory University Clinical Research Facility. Informed consent was obtained from adult patients or from the parents of patients <21 yr of age. Each patient served as his or her own control. Each patient was admitted on one of two double crossover protocols and five were studied in each protocol group. Either the patient entered on a low dietary phenylalanine which was increased the second week and decreased the third week (low-high-low) or in the reverse pattern (high-low-high). Patients equilibrated for 7 d after each change in dietary phenylalanine. Past plasma concentrations of phenylalanine on known intake and genotyping of parents were used to determine the amount of phenylalanine added to patient formulation for restriction and loading (23, 24) . Patients whose entering concentration of plasma phenylalanine was high either because of poor control or because of diet discontinuation for several years were on the highlow-high protocol. Five other patients who had been in consistently good dietary control entered the study on the low-high-low protocol.
The study diet was based on Phenylfree or Lofenalac as a phenylalanine-free amino acid source. A specified amount of tasteless Lphenylalanine was added to the formula during the loading phases. The (25) . This method used catechol-o-methyl transferase from rat liver to transfer a radioactive methyl group from S-adenosyl methionine to catecholamine, forming methyl catecholamine derivatives which were then characterized by radiochromatographic analysis. The assay was sensitive in urine to 120 pg/ml for dopamine.
Serotonin was determined by a radioimmunoassay developed by Peskar and Spector (26) using rabbit antibody prepared by coupling serotonin to bovine serum albumin. The antibody bound 50% of 3H-serotonin in the absence of free serotonin. Less than I ng of free serotonin was detected by standard displacement methods.
Urine organic acids were analyzed by gas chromatography on a HP 5992 gas chromatograph/mass spectroscope and quantitated on a HP 5790 gas chromatograph. Organic acids were extracted with ethyl acetate and ether and derivatized with trimethylsilane and bis-trimethylsilyl)trifluoracetamide (27). The level of sensitivity for phenylacids in urine was -''5 Mg. Specific recovery of phenylacetic, phenyllactic, and phenylpyruvic acids were 68, 91, and 58%, respectively. All calculations are corrected for these losses by parallel external and internal standards used during extraction, derivatization, and quantitation.
Renal clearances were calculated for phenylalanine, tyrosine, and tryptophan, from timed 24-h urine collections and mid-point plasma collections. Both specimens were quantitated for concentrations of amino acids and creatinine. The glomerular filtration rate (GFR) was calculated from the creatinine clearance, as were the rates of a specific amino acid filtration, excretion, and reabsorption using the following formulation (28): FA = GFR X PAA, EA = U.A X V, TAA = FAA -EA, where U was urinary amino acid concentration in mg/ml, V (urine volume) in ml/min, and PAA the plasma amino acid concentration in mg/ml. The FA (filtered aminoacid), EA (excreted aminoacid), and TAA (reabsorbed aminoacid) were expressed in mg/min. Percent reabsorption was calculated as TAA/FAA X 100.
Neuropsychological tests. Measurements of general intelligence and achievement were based on the Wechsler Intelligence Scales (The Wechsler Adult Intelligence Scale for adults and the WISC for children) and the WRAT. To determine the influence of phenylalanine concentrations on neuropsychological performance, a repeatable battery of tests was developed and administered as a baseline on admission to the study and at the end of each l-wk treatment period. A confounding variable inherent in tests given multiple times is subject learning. Two procedures were incorporated in the study design to reduce the artifacts due to learning. For one group of tests (type 1, Table I ), the subject was allowed to practice the task until the asymptote of the learning curve was reached. Any changes in performance after becoming maximally competent with the task then reflected experimental manipulation of the patient. This procedure would not eliminate learning artifacts from a second group of tests (type 2, Table I ). Because of this limitation, equivalent forms of this latter group of tests were developed to be given at the end of each of the experimental conditions. Table I lists the test names and the neuropsychological variables they measured.
Interpretation of data. Data are arrayed for all subjects in tabular form (Tables II, III, The results of dopamine and serotonin excretion are arrayed in Table III . Results were normalized to creatinine excretion. Interindividual variation in dopamine excretion was great. In general, the patients who were on the low-high-low protocol and had been on consistent dietary management before the study achieved higher levels of dopamine excretion than did those patients in the high-low-high group who were not well controlled immediately before the study. This kind of separation was not seen for serotonin excretion. Changes in dopamine excretion varied inversely with changes in plasma phenylalanine in 9 of 10 patients. The inverse relationship of changes in plasma phenylalanine concentrations and urinary dopamine excretion are graphed in Fig. 2 . Solid symbols represent patients on the high-low-high protocol. Open symbols represent patients on low-high-low protocols. Results from all patients cluster in quadrants I and III regardless of the protocol (highlow-high or low-high-low) where quadrants I and III circumscribe an inverse relationship between plasma phenylalanine and urinary dopamine concentrations. Symbols in quadrant I show an increase in urine dopamine with decrease in plasma phenylalanine; those in quadrant III show a decrease in urine dopamine with an increase in plasma phenylalanine. Serotonin excretion did not vary directly with changes in phenylalanine.
Studies of membrane transport. To explore the possibility that increased concentrations of phenylalanine might competitively inhibit tyrosine or tryptophan uptake by the only plasma membrane transport function available for study in (Fig. 3) .
By comparing Figs. 2 and 3, one sees the inverse relationship between choice reaction time and dopamine excretion. As urinary dopamine fell, choice reaction time increased; that is, performance worsened. 
Discussion
Although mechanisms are unclear, the negative effect of increased blood phenylalanine on the developing human brain during infancy and early childhood is clear (1-7) . Early dietary restriction of phenylalanine prevents irreversible brain damage in children detected and treated for phenylalanine hydroxylase deficiency (2 (33) , who found that phenylalanine was a competitive inhibitor of rat brain tyrosine hydroxylase with a Ki = 1.7 X l0-s M. Since the concentrations of phenylalanine found by McKean (13) in his autopsy material averaged 8.4 X l0-4 M, such a mechanism of competitive inhibition was possible.
Phenylalanine may impair production of two psychoactive amines, namely dopamine and serotonin. Curtius et al. (34) described both decreased serotonin and dopamine synthesis in patients with high plasma phenylalanine concentrations caused by both phenylalanine hydroxylase deficiency and disorders in the tetrahydrobiopterin pathway. He also postulated competitive inhibition of both tyrosine and tryptophan hydroxylase by high phenylalanine at 1,500 and 600 gM concentrations, Phenylketonuria: a Modelfor Study ofPhenylalanine and Brain Function 25 25 test which required higher integrative function rather than fine 20 20 motor coordination. This was consistent over the whole group, 25 25 regardless of the age or competence of the patients. Although 20 24 many test batteries have been used in other surveys, the 21 32 computerized reaction time has not been reported (9, 11, 12 intellectual competency of a patient will control the amount its conform to of change produced by altered phenylalanine. The lower the bits dopamine individual's competency, the less change might be expected. ion fell when
The one major outlier (M.F.) did not show consistent trends in neuropsychological tests or in catecholamine excretion.
Despite attaining a concentration of 1,402 AM plasma phenylalanine, he excreted barely measurable amounts of derived organic acids. We can speculate that he has other "protective" functions. Possible mechanisms include impaired transport of phenylalanine across the blood brain barrier or an increased rate of phenylalanine incorporation into new protein synthesis. He could also have some "protective" variation in tyrosine hydroxylase which prevents inhibition by phenylalanine. He emphasizes the individuality of patients with phenylketonuria and the "sensitivity" of brain function to phenylalanine loading. The impairment in choice reaction time and decrease in dopamine excretion seen with increased plasma phenylalanine were reversible within the week periods studied. We are currently investigating a variety of repeatable neuropsychological and electrophysiological tests with which to assess performance in patients with varying competency, age, and achievement scores.
These data support the hypothesis that high concentrations of phenylalanine reversibly affect neuropsychological performance, probably through reduction in L-dihydroxyphenylalanine and dopamine production. The mechanisms may be through increased intracellular phenylalanine and competitive inhibition of brain tyrosine-3-hydroxylase. Whether intracellular concentrations of brain tyrosine are diminished is unknown. Although the concentrations of blood phenylalanine attained in our studies did not inhibit renal tubular reabsorption of tyrosine, it should be noted that the transport Km of phenylalanine, tyrosine, and tryptophan in brain and kidney differ. Additionally, the blood-brain barrier is saturated at normal plasma concentrations, whereas the renal tubular epithelium is not (16) (17) (18) (19) . Since nearly 80% of all brain dopamine is found in the corpus striatum, decreases in dopamine synthesis could affect neuropsychological functions that involve both the nigrostriatal and corticostriatal pathways (37) . This could explain the deterioration in response of our patients to a timed test, the Computerized Choice Reaction Time Test, which required integration of stimuli and a motor response. We have recently observed a change in the mean power frequency of electrical impulses detected by EEG in a different group of patients with phenylketonuria who were studied under similar clinical research protocols (38) . This type of electrophysiological approach could assist in anatomical localization of changes in brain function.
